Cronos Group Inc.
CRON evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for CRON—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · CRON
Cronos Group Inc. (CRON) is a Canadian cannabis company focused on producing and selling cannabis products, including rare cannabinoids, with a strong cash position and improving profitability.
Key risk: Regulatory uncertainty
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Market Cap
$1.25B
Cash Runway
—
Lead Asset
Spinach®
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 1 pipeline candidate · 1 clinical trial for Cronos Group Inc..
Cronos Group Inc. (CRON) is a Canadian cannabis company focused on producing and selling cannabis products, including rare cannabinoids, with a strong cash position and improving profitability.
- Cash and cash equivalents of $467.0M as of 2026-06-30 [sec].
- Total revenue of $70.6M for the three months ended June 30, 2026 [sec].
- Net income of $32.1M for the three months ended June 30, 2026 [sec].
- Shareholders' equity of $1,093.9M as of 2026-06-30 [sec].
- Adjusted EBITDA improved to $18.2M for the three months ended June 30, 2026, up 357% year-over-year [sec_mda · as of 2026-08-06].
What works
- Strong cash position of $467.0M as of 2026-06-30 provides liquidity for operations and strategic investments [sec].
- Revenue growth: net revenue before excise taxes increased to $70.6M in Q2 2026 from $44.3M in Q2 2025 [sec_mda · as of 2026-08-06].
- Profitability improvement: net income of $32.1M in Q2 2026, with Adjusted EBITDA up 357% year-over-year [sec_mda · as of 2026-08-06].
- Focus on rare cannabinoids may differentiate products in the market [sec_mda · as of 2026-08-06].
What to weigh
- Cash and cash equivalents decreased 41% from $791.8M as of December 31, 2025 to $467.0M as of June 30, 2026 [sec_mda · as of 2026-08-06].
- Regulatory uncertainty: U.S. federal and state laws regarding cannabis and hemp-derived cannabinoids remain unclear [sec_mda · as of 2026-08-06].
- Operating expenses increased 12% on a constant currency basis in Q1 2026 due to higher salaries, transaction costs, and product development costs [sec_mda · as of 2026-05-11].
- The company faces risks from insufficient cash flow or capital to execute its business plan [sec_mda · as of 2026-08-06].
From the filings
Quoted directly from source documents.
Cash and cash equivalents decreased significantly from year-end 2025 to mid-2026.
“Cash and cash equivalents | $ | 467,019 | | | $ | 791,794 | | | $ | (324,775) | | | (41) | %”
SEC MD&A · August 6, 2026
Net revenue before excise taxes increased in Q2 2026 compared to Q2 2025.
“Net revenue, before excise taxes | $ | 70,597 | | $ | 44,252”
SEC MD&A · August 6, 2026
Adjusted EBITDA improved significantly in Q2 2026.
“Adjusted EBITDA | $ | 18,167 | | | $ | 3,977 | | | $ | 14,190 | | | 357 | %”
SEC MD&A · August 6, 2026
The company faces regulatory uncertainty regarding U.S. cannabis laws.
“laws and regulations and any amendments thereto applicable to our business and the impact thereof, including uncertainty regarding the application of U.S. state and federal law to cannabis and U.S. hemp (including CBD and other U.S. hemp-derived cannabinoids) products”
SEC MD&A · August 6, 2026
Risks & what to watch (4)›
Key risks
- Regulatory uncertainty — Unclear U.S. federal and state laws on cannabis and hemp-derived cannabinoids [sec_mda · as of 2026-08-06].
- Cash burn — Cash decreased 41% from Dec 2025 to June 2026, raising sustainability concerns [sec_mda · as of 2026-08-06].
- Execution risk — Potential failure to realize growth opportunities or secure capital [sec_mda · as of 2026-08-06].
- Operating cost increases — Operating expenses rose 12% in Q1 2026 due to higher salaries and development costs [sec_mda · as of 2026-05-11].
What to watch
- Revenue growth trajectory and ability to sustain profitability [sec_mda · as of 2026-08-06].
- Cash burn rate and any changes in liquidity position [sec_mda · as of 2026-08-06].
- Regulatory developments in U.S. cannabis and hemp markets [sec_mda · as of 2026-08-06].
- Progress on rare cannabinoid product differentiation and market acceptance [sec_mda · as of 2026-08-06].
Sources: SEC MD&A · Generated August 26, 2026 · How we verify sources →
Run Cronos Group Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Cronos Group Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
Profitable (positive operating cash flow)
D/E 0.06 · 0% dilution
No tracked pipeline phase
1 candidate
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
189
Total value held
$85.8M
| Holder | Shares | Value |
|---|---|---|
| d. e. shaw & co., inc. | 7,618,227 | $19.1M |
| dimensional fund advisors lp | 2,679,051 | $6.7M |
| susquehanna international group, llp | 2,169,367 | $5.4M |
| renaissance technologies llc | 2,009,549 | $5.0M |
| prelude capital management, llc | 1,500,000 | $3.8M |
| cibc world market inc. | 1,346,820 | $3.4M |
| jane street group, llc | 1,043,675 | $2.6M |
| mmcap international inc. spc | 999,490 | $2.5M |
| quinn opportunity partners llc | 969,033 | $2.4M |
| cdc financial, inc. | 926,832 | $2.3M |
Showing top 10 of 189 institutional holders of Cronos Group Inc.. Open the full 13F history after sign-in.
Short Interest
as of Apr 21, 2026- % of float
- 2.0%
- Days to cover
- 3.7
- Shares short
- 3,828,177
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
CRON short interestGovernance
Frequently asked questions
What is the AI investment thesis for Cronos Group Inc.?
Cronos Group Inc. (CRON) is a Canadian cannabis company focused on producing and selling cannabis products, including rare cannabinoids, with a strong cash position and improving profitability.
Who is the CEO of Cronos Group Inc.?
Mr. Michael Ryan Gorenstein J.D. is the chief executive officer of Cronos Group Inc. (CRON).
Where is Cronos Group Inc. headquartered?
Cronos Group Inc. (CRON) is headquartered in Stayner, ON, Canada.
What therapeutic areas does Cronos Group Inc. focus on?
Cronos Group Inc. develops therapies across Cardiovascular.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.